Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain tumor labels could guide better treatments

NCT ID NCT05259605

Knowledge-focused Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting data from 1,650 people with various brain tumors to see if the updated 2021 WHO classification system helps doctors group patients more accurately and choose better treatments. Researchers will track responses to therapy, survival, and tumor features over 5 years. The goal is to create provisional treatment guidelines for newly defined tumor types based on real-world experience.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better classify brain tumors and choose more effective treatments based on the latest diagnostic criteria.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may take years and might not change current practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,650 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jul 2038

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with newly diagnosed or recurrent primary brain tumours, notably those considered to be very rare brain tumours or rare subtypes of common brain tumours will be included. Patients diagnosed between 2011 and 2025.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Age ≥ legal age of consent * Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest * Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exception: only tissue from first surgery is allowed for Cohort 16. * Available MRI/CT scans from primary brain tumour at initial diagnosis * Patient's consent Deceased patient: The clinical data and/or biological material and/or CT/MRI/PET images can be accessed and used if at least one of the following three conditions is met: * The patient agreed beforehand in his/her lifetime to a further use of his/her data and/or biological material and/or CT/MRI/PET images, or, * There is consent of a relative to use data and/or biological material and/or CT/MRI/PET images of the deceased patient, or, * There is a reference to a corresponding legal declaration covering the exemption in case of the impossibility or disproportion of getting access to an informed consent (e.g., causing strain on relatives of deceased patients). Additionally, in all cases the following three points need to be fulfilled: * No documentation of previous objection of the patient to the (re-)use of their data, biological material, CT/MR/PET images for research purposes * A notification to an ethics committee for the re-use of these data, biological material and CT/MRI/PET images * Any other national requirements are fulfilled, if applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Choroid plexus tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central nervous system melanocytic neoplasm choroid plexus neoplasm Choroid Plexus Neoplasms diffuse midline glioma, H3 K27M-mutant embryonal neoplasm ependymoma germ cell tumor glioma hemangioblastoma hemangiopericytoma mixed neuronal-glial tumor Neoplasms, Germ Cell and Embryonal pineal body neoplasm Pinealoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Choroid plexus tumor Diffuse midline glioma, H3 K27M-mutant Embryonal tumor Ependymoma Germ cell tumor GLIOMA Glioneuronal tumor Hemangioblastoma Hemangiopericytoma Melanocytic tumor of CNS Pineal tumor Pineal tumors Tumor of the sellar region

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    42 sites in 12 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Delta - Campus Rumbeke

    RECRUITING

    Roeselare, Belgium

  • Azienda Ospedaliero-Universitaria Careggi

    RECRUITING

    Florence, Italy

  • C.H.U. Sart-Tilman

    RECRUITING

    Liège, Belgium

  • CHU Lyon - Hopital neurologique Pierre Wertheimer

    RECRUITING

    Lyon, France

  • Centre Hospitalier Universitaire Vaudois

    RECRUITING

    Lausanne, Switzerland

  • Centro Hospitalar Universitario Lisboa Norte - Hospital Sta. Maria

    RECRUITING

    Lisbon, Portugal

  • Diagnostic & Therapeutic Center of Athens Hygeia Hospital S.A.

    RECRUITING

    Athens, Greece

  • Erasmus MC

    RECRUITING

    Rotterdam, Netherlands

  • Hopital de La Timone

    RECRUITING

    Marseille, France

  • Hopital la Pitie-Salpetriere

    RECRUITING

    Paris, France

  • Hospital Clinic de Barcelona

    RECRUITING

    Barcelona, Spain

  • Hospital De La Santa Creu I Sant Pau

    RECRUITING

    Barcelona, Spain

  • Hospital Duran i Reynals

    RECRUITING

    L'Hospitalet de Llobregat, Spain

  • Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)

    RECRUITING

    Barcelona, Spain

  • IRCCS Ospedale San Raffaele

    RECRUITING

    Milan, 20132, Italy

  • IRCCS-Regina Elena National Cancer Center

    RECRUITING

    Roma, 00144, Italy

  • Innsbruck Universitaetsklinik

    RECRUITING

    Innsbruck, Austria

  • Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Institut Jules Bordet

    RECRUITING

    Anderlecht, Belgium

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil - EPE

    RECRUITING

    Lisbon, Portugal

  • Istituto Neurologico Carlo Besta

    RECRUITING

    Milan, Italy

  • Istituto Oncologico Veneto

    RECRUITING

    Padova, Italy

  • Knappschaft Krankenhaus Langendreer

    RECRUITING

    Bochum, 44892, Germany

  • Leiden University Medical Centre

    RECRUITING

    Leiden, Netherlands

  • NHS Lothian - The Royal Infirmary Of Edinburgh

    RECRUITING

    Edinburgh, EH16 4SA, United Kingdom

  • Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care

    RECRUITING

    Newcastle upon Tyne, United Kingdom

  • Nottingham University Hospitals NHS Trust - City Hospital

    RECRUITING

    Nottingham, United Kingdom

  • Onze Lieve Vrouw Ziekenhuis

    RECRUITING

    Aalst, Belgium

  • Oslo University Hospital - Radiumhospitalet

    RECRUITING

    Oslo, Norway

  • Ospedale Bellaria-Bologna

    RECRUITING

    Bologna, Italy

  • Ospedale San Giovanni - Dipartimento Neuroscienze

    RECRUITING

    Torino, Italy

  • The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

    RECRUITING

    Amsterdam, Netherlands

  • UniversitaetsSpital Zurich - Neurology Clinic

    RECRUITING

    Zurich, Switzerland

  • Universitaetsklinikum - Essen

    RECRUITING

    Essen, 45147, Germany

  • Universitaetsklinikum Bonn

    RECRUITING

    Bonn, 53105, Germany

  • Universitaetsklinikum Jena

    RECRUITING

    Jena, 07447, Germany

  • Universitaetsklinikum Koeln

    RECRUITING

    Cologne, 50937, Germany

  • Universitaetsklinikum Leipzig-Klinik fuer Strahlentherapie und Radioonkologie

    RECRUITING

    Leipzig, Germany

  • Universitaetsklinikum Regensburg

    RECRUITING

    Regensburg, Germany

  • Universitaetsklinikum Wien - AKH unikliniken

    RECRUITING

    Vienna, Austria

  • Universitair Ziekenhuis Brussel

    RECRUITING

    Brussels, Belgium

  • University Hospital Frankfurt -Senckenberg Institute of Neurooncology

    RECRUITING

    Frankfurt, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.